Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04125745 · ClinicalTrials.gov registry record · Phase 2
Oral CXA-10 in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Gladwin, Mark, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04125745 is a Phase 2 study that was terminated before completion, run by Gladwin, Mark, MD. The registered enrollment target is 1 participants.
The verdict
NCT04125745, a Phase 2 study, was terminated before completion, sponsored by Gladwin, Mark, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on changes in hemodynamics, exercise capacity, cardiovascular function and patient reported outcomes.
Interventions
- DRUG CXA-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04125745
The ClinicalTrials.gov registry entry for NCT04125745 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gladwin, Mark, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CXA-10 is the first listed.
NCT04125745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04125745 about?
NCT04125745 is a clinical study titled "Oral CXA-10 in Pulmonary Arterial Hypertension". The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on changes in hemodynamics, exercise capacity, cardiovascular function and p...
What is the current status of trial NCT04125745?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-10-31. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT04125745?
The interventions under investigation include: CXA-10 (DRUG).
Who is sponsoring clinical trial NCT04125745?
This trial is sponsored by Gladwin, Mark, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.